During this panel conversation, you will hear from Private Company Board Members and Private Company executives about the transition that Technology Companies Boards manage as their companies grow. You will hear also about how Technology companies usually start their Boards with scientific, medical, or technical advisors, and then evolve into a Board that handles more Governance related activities as the company takes shape. You will hear about the role played by the private company's board - and specifically private directors in guiding the private company’s strategy and Board refreshment and succession in this progression. Directors and C-level executives of private companies will also share their experience building or re-building the Board with the necessary skill-sets.
This event is designed for private company business owners and management, private equity and venture capital firm management, board members, prospective board members, and those who work directly with private boards.
Key takeaways addressed will be: • What are the stages of Tech Company Boards, and when is the company ready to transition? • What methods are used to evolve the Board as the company grows? • How do Boards retain the technical expertise of the original board while making these changes? Our Panelists: Carol Meyers: Carol Meyers is Chief Marketing Officer of Rapid7, a leader in analytics solutions for security and IT operations. As an executive, Meyers has participated in four successful IPOs, including Rapid7, LogMeIn, and Unica Corporation. Previously in her career, Meyers was the VP of Sales for Shiva Corporation and held roles in sales, marketing and finance at Lotus and GE. In addition to her role as a marketing executive, Meyers also serves on the board of directors for Emarsys and MineralTree, and as an advisor to Duo Security, SocialRep and Wordstream.
Rick Eno: RIchard P. Eno has served as CEO and Board Member for two publicly traded, early stage, renewable materials companies. In these companies, he has led the commercialization of new, innovative products based upon the application of industrial biotechnology. These products serve a broad range of industrial markets including those targeted by renewable chemistry as well as biodegradable plastics. In each of these companies, Mr. Eno worked closely with the entire Board to evolve desired performance metrics, culture, governance and business processes to best align with company needs.
In addition to his experience leading innovative companies, Mr. Eno has spent over 15 years in management consulting focused on chemicals, energy and advanced materials. In this capacity, Mr Eno has advised clients around the world on critical business strategy, operational, organizational and technology issues. His clients included several of the largest companies in the world. He has also mentored a number of clean technology start-ups offering innovative solutions for water purification, sustainable finance and plastics waste management.
Mr. Eno has served as Vice Chairman of the Industrial and Environmental Governing Board for the Biotechnology Industry Association and is currently on the Advisory Board for the Atkinson Center for a Sustainable Future at Cornell University. He also serves on the Advisory Board for Cornell's School of Chemical and Biomolecular Engineering. He is a member of the President's Council for Ceres, the sustainability non-profit driving a sustainable future through the engagement of influential investors and companies.
Mr. Eno is a Trustee and on the Executive Committee for the Winchester Community Music School which provides music education every year to over 850 students across 30 towns. Mr. Eno has a Chemical Engineering degree from Cornell University and a Masters in Business Administration from the University of Houston. He is a Chartered Financial Analyst and a member of the Boston Security Analysts Society.
Payal Agrawal: Payal is a Principal at .406 Ventures, where she focuses on digital health investing. .406 Ventures is a Boston-based venture capital firm with ~$650M under management. The firm invests in enterprise-oriented startups in sectors including digital health, cybersecurity, and data & cloud. Payal’s portfolio includes Annum Health, Axial Healthcare, CloudHealth (acquired by VMWare), Event Farm, Jisto (acquired by Trilio Data), Nomad Health, Redox, Trilio Data, WelbeHealth, Wellist, and Virtudent. Previously, Payal co-founded a company called SpotRocket to help students discover high potential startups to work for. Payal has also worked at Eventbrite, Spectrum Equity, and J.P. Morgan. Payal received her MBA, with Distinction, from Harvard Business School and her BS in Electrical Engineering and minor in Management from MIT. She is a Boston native, and she and her husband, who is a physician at Brigham and Women’s Hospital, and daughter live in Cambridge.
Our Moderator: Adam Rosenberg: Adam Rosenberg joined Rodin in September 2015 as President and Chief Executive Officer. Adam previously co-founded a number of innovative companies in the Boston/Cambridge area, including Teleos Therapeutics, a biotechnology company leveraging unique insights in zebrafish chemical biology to discover new treatments for CNS disorders; Clean Membranes, a nanomaterials company based on MIT technology; Link Medicine, focused on developing novel disease-modifying neurodegenerative treatments; and Faber Law Group, a boutique business law firm focused on the biotechnology sector.
Previously, Adam was a principal with Ovation Capital Partners, and has served as strategic advisor and interim executive to multiple companies in biotechnology and digital health. Adam also advised the production of A Late Quartet, a feature film starring Christopher Walken, Philip Seymour Hoffman and Catherine Keener, centered on a cellist in a world-class string quartet who is diagnosed with Parkinson’s disease. In addition to Rodin, he also serves on the Board of Directors of Adeo Health Sciences, a venture-backed company focused on enabling the early introduction of allergens for infants.